menu
    • menu
    [{"orgOrder":0,"company":"Biophta","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Biophta \/ HTL Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Biophta \/ HTL Biotechnology"},{"orgOrder":0,"company":"Biophta","sponsor":"UI Investissement","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Biophta \/ UI Investissement","highestDevelopmentStatusID":"4","companyTruncated":"Biophta \/ UI Investissement"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NCX 1728","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nicox SA \/ Glaukos","highestDevelopmentStatusID":"4","companyTruncated":"Nicox SA \/ Glaukos"},{"orgOrder":0,"company":"Biophytis","sponsor":"BPI","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2021","type":"Funding","leadProduct":"Macuneos","moa":"PPA-alpha receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ BPI","highestDevelopmentStatusID":"4","companyTruncated":"Biophytis \/ BPI"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"PulseSight Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PST-809","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"PulseSight Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PulseSight Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"PulseSight Therapeutics \/ Pureos Bioventures"},{"orgOrder":0,"company":"Variant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"VAR002","moa":"CRX gene","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Variant","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Variant \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Variant \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Variant

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            Variant

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VAR002

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VARIANT Gets EMA Positive Feedback for Innovative Gene Therapy VAR002

                            Details : VAR002 is a recombinant adeno-associated viral (rAAV) vector initially developed to treat Leber's congenital amaurosis, Retinitis pigmentosa, and Cone-rod dystrophy due to a mutation in the CRX gene.

                            Product Name : VAR002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 03, 2025

                            Lead Product(s) : VAR002

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nicox SA

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            Nicox SA

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCX 1728

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Glaukos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

                            Details : Under the license agreement, Glaukos will fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and other retinal diseases.

                            Product Name : NCX 1728

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 23, 2024

                            Lead Product(s) : NCX 1728

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Glaukos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biophta

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            Biophta

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : HTL Biotechnology

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            BIOPHTA Raises 6.5M Euros Funding to Transition its New Standard of Care for Eye Diseases

                            Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.

                            Product Name : BO-001

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 06, 2024

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : HTL Biotechnology

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biophta

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            Biophta

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : UI Investissement

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            BIOPHTA Raises €6.5M For Eye Disease Therapy Clinical Transition

                            Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.

                            Product Name : BO-001

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 06, 2024

                            Lead Product(s) : BO-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : UI Investissement

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PulseSight Therapeutics

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            PulseSight Therapeutics

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PST-809

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Pureos Bioventures

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PulseSight Launches to Advance Non-Viral Gene Therapies for Severe Retinal Diseases

                            Details : PST-809, is a potential first-in-class therapy for wet age-related macular degeneration that comprises a dual-gene plasmid encoding for anti-VEGF, aflibercept, together with decorin.

                            Product Name : PST-809

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 27, 2024

                            Lead Product(s) : PST-809

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Pureos Bioventures

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biophytis

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            Biophytis

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macuneos

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : BPI

                            Deal Size : $1.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Biophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry...

                            Details : Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathi...

                            Product Name : BIO201

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            April 29, 2021

                            Lead Product(s) : Macuneos

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : BPI

                            Deal Size : $1.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SparingVision

                            France arrow
                            APGA Annual Conference
                            Not Confirmed

                            SparingVision

                            France arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPVN06

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retina...

                            Details : SPVN06 uses a gene therapy-based approach independent of mutated genes and by a single subretinal injection of proprietary neurotrophic factors, aims at stopping and preventing the degeneration of photoreceptors leading to blindness.

                            Product Name : SPVN06

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            June 30, 2020

                            Lead Product(s) : SPVN06

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth